Corticosteroids and plasma exchange successful

Article

Pulsed intravenous corticosteroids and plasma exchange (PE) is more effective than standard monotherapy for treating acute optic neuritis of neuromyelitis optica (NMO).

Pulsed intravenous corticosteroids and plasma exchange (PE) is more effective than standard monotherapy for treating acute optic neuritis of neuromyelitis optica (NMO).

Dr Harold Merle and his team, Centre Hospitalier Universitaire de Fort de France, Hôpital Pierre Zobda-Quitman, Martinique, France, devised an investigation on 52 optic neuritis patients who were treated from 1 January 1995 to 31 December 31 2010.

Pulsed intravenous corticosteroids were used to treat 36 patients and pulsed intravenous corticosteroids plus PE was used to treat 16 patients. Ophthalmic examinations were performed at least six months after optic neuritis treatment. The Snellen scale and the logarithmic scale of Early Treatment Diabetic Retinopathy Study were used to measure visual acuity and visual field. Optical coherence tomography was used to measure retinal peripapillary fibre thickness.

The final visual acuity was 20/400 and 20/50 in the corticosteroid group and the PE group, respectively. The gain in visual acuity was 20/200 and 20/30 in the corticosteroids and PE groups, respectively.

Out of the corticosteroid group, 19 patients had a poor visual outcome, compared to just two patients in the PE group. According to the multivariate analysis, PE treatment was the sole independent factor linked to a visual acuity greater than 20/200 and it is more effective than standard monotherapy with corticosteroids.

The study is featured in the Archives of Ophthalmology and the abstract can be found here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.